Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSDZ8U)

Drug Name
Rintatolimod Drug Info
Synonyms Ampligen
Indication
Disease Entry ICD 11 Status REF
Chronic fatigue syndrome 8E49 phase 3 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [2]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
122130925
TTD Drug ID
DMSDZ8U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Download the Complete Related Drug List
Drug(s) Targeting HUMAN toll-like receptor 3 (TLR3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Polyinosinic:polycytidylic acid DM4VZCW Middle East Respiratory Syndrome (MERS) 1D64 Investigative [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN toll-like receptor 3 (TLR3) TT1CN09 TLR3_HUMAN Agonist [3]

References

1 ClinicalTrials.gov (NCT00215813) Ampligen in Chronic Fatigue Syndrome. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04379518) Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients. U.S. National Institutes of Health.
3 Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70.
4 Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019 Apr 7;2019:6491738. doi: 10.1155/2019/6491738.